Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | PANK3 | Q9H999 | 11/20 | 0.51 |
| ▸ | ME2 | P23368 | 2/20 | 0.43 |
| ▸ | ME1 | P48163 | 2/20 | 0.43 |
| ▸ | ME3 | Q16798 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425899 | 0.82 | GPR119 (0.53) | OGAPANK3ALDH1A1 | |
| SCHEMBL5237033 | 0.79 | PANK3 (0.57) | PANK3ME2ME1ME3KDM4E | |
| SCHEMBL10136514 | 0.78 | PANK3 (0.57) | SMOPANK3KDM4EALDH1A1 | |
| SCHEMBL5234572 | 0.78 | PANK3 (0.55) | PANK3ME2ME1ME3 | |
| SCHEMBL31627497 | 0.78 | ALDH1A1 (0.51) | OGAPANK3ALDH1A1 | |
| SCHEMBL21447902 | 0.78 | OGA (0.54) | OGASMOKDM4EALDH1A1AKR1C3 | |
| SCHEMBL21551525 | 0.77 | ME2 (0.66) | ME2ME1ME3ALDH1A1AKR1C3 | |
| SCHEMBL26027621 | 0.77 | PANK3 (0.60) | SMOPANK3KDM4EALDH1A1ADRB2 | |
| SCHEMBL2456399 | 0.76 | ME2 (0.47) | OGAME2ME1ME3KDM4E | |
| SCHEMBL16397570 | 0.76 | PANK3 (0.57) | PANK3ME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | OGA 4344/4885SMO 1761/4885PANK3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.